Fig 2: Immunohistochemistry (IRS, nuclear score) of ZYX expression in NSCLC cells in relation to the histological grade. The analysis for NSCLC (A,D), lung SCC (B,E), and lung AC (C,F). Dunn’s multiple comparisons test.

Fig 3: Immunohistochemistry (IRS, nuclear score) of ZYX expression in NSCLC cells in relation to tumor size (pT). Results for NSCLC (A,D), SCC (B,E), and AC (C,F) subtypes. Dunn’s multiple comparisons test (* p < 0.05).

Fig 4: Zyx−/− mice display macrothrombocytopenia.A, B Platelet count (A) and volume (B) were analyzed in whole blood from WT (n = 21) and Zyx−/− (n = 17) mice. Means are indicated by horizontal lines. ***P < 0.001 compared with WT mice by Mann–Whitney test in (A) and unpaired Student’s t-test with Welch correction in (B). C Representative images of Wright–Giemsa stained blood smears from WT and Zyx−/− mice (original magnification × 1,000). Scale bar: 10 μm. Platelets were indicated with arrows. D Representative transmission electron microscopy (TEM) images of WT and Zyx−/− platelets (original magnification ×13,500). Scale bar: 1 μm. Images were obtained from five mice in each genotype in (C) and (D). E WT and Zyx−/− mice were intravenously injected with NHS-biotin, and peripheral blood was taken at the indicated time points after injection. The percentage of biotinylated platelets was determined by flow cytometry; n = 10 mice per genotype. Data are expressed as means ± SD. F Serum TPO levels in WT and Zyx−/− mice; n = 7 mice per genotype. Means are indicated by horizontal lines.

Fig 5: Expression of ZYX in the IMR-90 normal lung fibroblast cell line and in NSCLC cell lines: NCI-H1703 (lung squamous cell carcinoma) and NCI-H522 (lung adenocarcinoma). Western Blot (A) and densitometric analysis (B) of ZYX protein levels. ZYX mRNA expression in the cell lines (C). ZYX expression levels determined by measuring fluorescence intensity in the cell lines (D). Bonferroni multiple comparisons test (*** p < 0.001; ** p < 0.01; * p < 0.05).